InterVenn Biosciences and Aranscia Expand Commercialization Partnership for GlycoKnow™ Ovarian Cancer Diagnostic Test

Aranscia's Technology Platform to Accelerate InterVenn's Research and Commercialization Initiatives SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 30, 2026 /PRNewswire/ — InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions,…

Read the full release →

News provided by PR Newswire.